A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy wanes ...

GSK's (GSK) stock rises as the company's Arexvy shot could see expanded CDC recommendations for RSV protection in at-risk ...

Researchers from the Wesfarmers Center of Vaccines and Infectious Diseases, based at The Kids Research Institute Australia, ...

SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and ...

Although we can’t control what others chose to do about handwashing and social distancing, we can decide to protect our ...

Knowledge of respiratory syncytial virus (RSV) disease and RSV vaccine eligibility is low among hospitalized older adults.

After decades of fits and starts, scientists finally got the world’s first vaccines against respiratory syncytial virus ...

Adults diagnosed with RSV-associated acute respiratory infection face nearly triple the risk of death within 1 year compared ...

Adults suffering from respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a nearly threefold ...

Adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) are likely to be at a 2.7-fold ...

Adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) are likely to be at a 2.7-fold ...

A major study presented today at ESCMID Global 2025 has revealed that adults with respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) face a 2.7-fold higher risk of death ...